|Bid||38.80 x 800|
|Ask||39.45 x 800|
|Day's Range||37.57 - 39.37|
|52 Week Range||23.81 - 154.80|
|Beta (5Y Monthly)||1.67|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 14, 2023 - Feb 20, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.75|
10x Genomics, Inc. ( NASDAQ:TXG ), might not be a large cap stock, but it saw a significant share price rise of over...
10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the commercial availability of BEAM (Barcode Enabled Antigen Mapping), a kitted solution for antibody and T-cell receptor (TCR) discovery. Built on top of 10x's industry-leading Chromium Single Cell Immune Profiling product, BEAM's proprietary antigen screening approach is fast and robust, delivering hundreds of antigen-receptor pairs with single cell gene expression. Th
10x Genomics ( NASDAQ:TXG ) Third Quarter 2022 Results Key Financial Results Revenue: US$131.1m (up 4.6% from 3Q 2021...